Real-world experience with edoxaban for anticoagulation in children at risk for coronary artery thrombosis

Apixaban Anticoagulation in Children and Young Adults Supported With the HeartMate 3 Ventricular Assist Device

(2023) Ryan L. Kobayashi et al.   ASAIO JOURNAL

Edoxaban for Thromboembolism Prevention in Pediatric Patients with Cardiac Disease

(2022) Michael A. Portman et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Impact of Renal Function on Anti-factor Xa Activity Concentrations with Edoxaban Use in Patients with Non-valvular Atrial Fibrillation

(2022) Ryohei Ono et al.   DRUGS IN R&D

Pharmacokinetic Modeling and Simulation Support for Age‐ and Weight‐Adjusted Dosing of Dabigatran Etexilate in Children with Venous Thromboembolism

(2021) Daniel Röshammar et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

ENNOBLE-ATE trial: an open-label, randomised, multi-centre, observational study of edoxaban for children with cardiac diseases at risk of thromboembolism

(2021) Mihir D. Bhatt et al.   CARDIOLOGY IN THE YOUNG

Thromboprophylaxis for Children Post‐Fontan Procedure: Insights From the UNIVERSE Study

(2021) Brian W. McCrindle et al.   Journal of the American Heart Association

Factors Associated With Edoxaban Concentration Among Patients With Atrial Fibrillation

(2021) Shin-Yi Lin et al.   Frontiers in Pharmacology

Use of Direct Oral Anticoagulants in Children and Adolescents

(2020) Manuela Albisetti   Hamostaseologie

Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr Phase 3 dose-exposure-response evaluation

(2020) Guy Young et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Validation and clinical application of dried blood spot assay for quantitative assessment of edoxaban in healthy adults

(2020) Ling He et al.   Bioanalysis

Medium‐Term Complications Associated With Coronary Artery Aneurysms After Kawasaki Disease: A Study From the International Kawasaki Disease Registry

(2020) Brian W. McCrindle et al.   Journal of the American Heart Association

A multi-national trial of a direct oral anticoagulant in children with cardiac disease: Design and rationale of the Safety of ApiXaban On Pediatric Heart disease On the preventioN of Embolism (SAXOPHONE) study

(2019) R. Mark Payne et al.   AMERICAN HEART JOURNAL

Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies

(2019) Paul Monagle et al.   Lancet Haematology

Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial

(2019) Christoph Male et al.   Lancet Haematology

Difference between persistent aneurysm, regressed aneurysm and coronary dilation in Kawasaki disease: an Optical Coherence Tomography study

(2018) Audrey Dionne et al.   CANADIAN JOURNAL OF CARDIOLOGY

International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants

(2018) Robert Gosselin et al.   THROMBOSIS AND HAEMOSTASIS

Safety and Efficacy of Warfarin Therapy in Kawasaki Disease

(2017) Annette L. Baker et al.   JOURNAL OF PEDIATRICS

Kawasaki Disease

(2016) Jane W. Newburger et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa

(2015) Dolly A. Parasrampuria et al.   CLINICAL PHARMACOKINETICS

Quality of life assessment in children commencing home INR self-testing

(2013) Sophie Jones et al.   THROMBOSIS RESEARCH

Three Linked Vasculopathic Processes Characterize Kawasaki Disease: A Light and Transmission Electron Microscopic Study

(2012) Jan Marc Orenstein et al.   PLoS One